Buy Like Buffett
Watchlist

Flagship explainer

How NovoCure Limited makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$655M · 100%Cost of revenue$167M · 25%Gross profit$488M · 75%Operating income−$154M · −23%Income before tax−$136M · −21%Income tax−$23000 · −0%Net income−$136M · −21%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$655M100%
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
Cost of revenue$167M25%
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
$488M75%
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
−$154M−23%
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
Income before tax−$136M−21%
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
Income tax−$23000−0%
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
−$136M−21%
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001645113-26-000017 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full NovoCure Limited analysis at Buy Like Buffett